Pfizer Q1: Headwinds And Tailwinds From COVID-19
Executive Summary
The company reaffirmed 2020 sales and earnings financial guidance, highlighting the resiliency of the business amid a global pandemic, but Pfizer did highlight some potential business challenges.
You may also be interested in...
10 Non-COVID News Updates To Listen For In Second Quarter Reporting
The pandemic is expected to dominate the industry's second quarter earnings calls, which kick off on 16 July, but here are 10 other topics to listen for.
An Ambitious COVID-19 Vaccine Development Plan For Pfizer And BioNtech
Pfizer said it is dosing patients now with an mRNA-based vaccine and expects human data in May/June, with a goal to have a vaccine available for emergency use possibly by October.
An Ambitious COVID-19 Vaccine Development Plan For Pfizer And BioNtech
Pfizer said it is dosing patients now with an mRNA-based vaccine and expects human data in May/June, with a goal to have a vaccine available for emergency use possibly by October.